Objective To investigate the effect of sodium-glucose transporter 2(SGLT2)inhibitor and glucagon-like peptide-1(GLP1)receptor agonist in patients with type 2 diabetes mellitus(T2DM).Methods A total of 153 T2DM patients admitted to Siping City Central People's Hospital from February 2022 to March 2023 were selected and di-vided into control group 1(metformin treatment),control group 2(metformin+SGLT2 inhibitor treatment)and study group(metformin+SGLT2 inhibitor treatment+GLP-1 receptor agonist treatment)according to different treatment methods,51 cases in each group.Blood glucose indexes,islet function and adverse reactions were compared among the three groups.Results After treatment,fasting plasma glucose,2-hour postprandial plasma glucose and glycated hemoglobin A1c in 3 groups were lower than before treatment,control group 2 and study group were lower than control group 1,and study group was lower than control group 2,the differences were statistically significant(all P<0.05).Af-ter treatment,fasting insulin levels in 3 groups were reduced,and control group 2 and study group were higher than control group 1,and study group was higher than control group 2,homeostatic model assessment of insulin resistance was decreased,and both control group 2 and study group were lower than control group 1,and study group was lower than control group 2,the differences were statistically significant(both P<0.05).There was no significant difference in the incidence of adverse reactions among the three groups(P>0.05).Conclusion The application of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus was effective,which was conducive to improving blood glu-cose index and insulin function of patients,and does not increase adverse reactions,and has higher safety.
NETL
NSTL
万方数据
